Diagnostic Performance of [18F]F-FDG Positron Emission Tomography (PET) in Non-Ophthalmic Malignant Melanoma: A Systematic Review and Meta-Analysis of More Than 10,000 Melanoma Patients
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Search Strategy
2.2. Study Selection
- (1)
- Evaluated [18F]F-FDG PET, PET/CT, or PET/MRI as the diagnostic method to detect tumoral lesions in non-ophthalmic melanoma patients, including cutaneous melanoma, mucosal melanoma, and melanoma of unknown primary. For the sake of this review, we will refer to [18F]F-FDG PET, PET/CT, and PET/MRI with general terminology of [18F]F-FDG PET in the rest of the manuscript, unless particularly mentioned.
- (2)
- Compared [18F]F-FDG PET with histopathology, follow-up, or asynchronous multimodality imaging as the reference standard.
- (3)
- Provided adequate raw data to calculate true positive (TP), true negative (TN), false positive (FP), and false negative (FN) results.
2.3. Data Extraction
2.4. Statistical Analysis
3. Results
3.1. Study Characteristics
3.2. Diagnostic Performances
3.2.1. Patient-Level Diagnostic Performances
3.2.2. Lesion-Level Diagnostic Performances
4. Discussion
5. Conclusions
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- Matthews, N.H.; Li, W.-Q.; Qureshi, A.A.; Weinstock, M.A.; Cho, E.J.E.P. Epidemiology of melanoma. In Cutaneous Melanoma: Etiology and Therapy [Internet]; Codon Publications: Brisbane, Australia, 2017; pp. 3–22. [Google Scholar]
- Dimitriou, F.; Krattinger, R.; Ramelyte, E.; Barysch, M.J.; Micaletto, S.; Dummer, R.; Goldinger, S.M. The world of melanoma: Epidemiologic, genetic, and anatomic differences of melanoma across the globe. Curr. Oncol. Rep. 2018, 20, 87. [Google Scholar] [CrossRef]
- Society, A.C. Cancer Facts & Figures 2014; American Cancer Society: Atlanta, GA, USA, 2014. [Google Scholar]
- Apalla, Z.; Lallas, A.; Sotiriou, E.; Lazaridou, E.; Ioannides, D. Epidemiological trends in skin cancer. Dermatol. Pract. Concept. 2017, 7, 1. [Google Scholar] [CrossRef] [PubMed]
- Jadvar, H.; Colletti, P.M.; Delgado-Bolton, R.; Esposito, G.; Krause, B.J.; Iagaru, A.H.; Nadel, H.; Quinn, D.I.; Rohren, E.; Subramaniam, R.M.; et al. Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. J. Nucl. Med. 2017, 58, 2026–2037. [Google Scholar] [CrossRef] [PubMed]
- Gershenwald, J.E.; Scolyer, R.A.; Hess, K.R.; Sondak, V.K.; Long, G.V.; Ross, M.I.; Lazar, A.J.; Faries, M.B.; Kirkwood, J.M.; McArthur, G.A.; et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 2017, 67, 472–492. [Google Scholar] [CrossRef] [PubMed]
- Dinnes, J.; Di Ruffano, L.F.; Takwoingi, Y.; Cheung, S.T.; Nathan, P.; Matin, R.N.; Chuchu, N.; Ann Chan, S.; Durack, A.; Bayliss, S.E.; et al. Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma. Cochrane Database Syst. Rev. 2019, 7, CD012806. [Google Scholar] [CrossRef] [PubMed]
- Salameh, J.-P.; Bossuyt, P.M.; McGrath, T.A.; Thombs, B.D.; Hyde, C.J.; Macaskill, P.; Deeks, J.J.; Leeflang, M.; Korevaar, D.A.; Whiting, P. Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): Explanation, elaboration, and checklist. Bmj 2020, 370, m2632. [Google Scholar] [CrossRef]
- Higgins, J.P.; Thomas, J.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.J.; Welch, V.A. Cochrane Handbook for Systematic Reviews of Interventions; John Wiley & Sons: Hoboken, NJ, USA, 2019. [Google Scholar]
- Dwamena, B. MIDAS: Stata Module for Meta-Analytical Integration of Diagnostic Test Accuracy Studies; Statistical Software Components S456880; Boston College Department of Economics: Chestnut Hill, MA, USA, 2009. [Google Scholar]
- Nyaga, V.; Arbyn, M.; Aerts, M. METAPROP_ONE: Stata Module to Perform Fixed and Random Effects Meta-Analysis of Proportions; Statistical Software Components S457861; Boston College Department of Economics: Chestnut Hill, MA, USA, 2017. [Google Scholar]
- Acland, K.M.; O’Doherty, M.J.; Russell-Jones, R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J. Am. Acad. Dermatol. 2000, 42, 606–611. [Google Scholar] [CrossRef]
- Aerts, M.A.; Mana, F.; Neyns, B.; de Looze, D.; Reenaers, C.; Urbain, D. Small bowel metastases from melanoma: Does videocapsule provide additional information after FDG positron emission tomography? Acta Gastro-Enterol. Belg. 2012, 75, 219–221. [Google Scholar]
- Agrawal, A.; Pantvaidya, G.; Murthy, V.; Prabhash, K.; Bal, M.; Purandare, N.; Shah, S.; Rangarajan, V. Positron Emission Tomography in Mucosal Melanomas of Head and Neck: Results from a South Asian Tertiary Cancer Care Center. World J Nucl Med. 2017, 16, 197–201. [Google Scholar] [CrossRef]
- Akcali, C.; Zincirkeser, S.; Erbagcý, Z.; Akcali, A.; Halac, M.; Durak, G.; Sager, S.; Sahin, E. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT. J. Int. Med. Res. 2007, 35, 547–553. [Google Scholar] [CrossRef]
- Albano, D.; Familiari, D.; Fornito, M.C.; Scalisi, S.; Laudicella, R.; Galia, M.; Grassedonio, E.; Ruggeri, A.; Ganduscio, G.; Messina, M.; et al. Clinical and Prognostic Value of F-18-FDG-PET/CT in the Restaging Process of Recurrent Cutaneous Melanoma. Curr. Radiopharm. 2020, 13, 42–47. [Google Scholar] [CrossRef] [PubMed]
- Andersen, J.A.S.; Spatzek, A.D.; Vilstrup, M.H.; Grupe, P.; Hess, S.; Holdgaard, P.C.; Bastholt, L.; Gerke, O.; Hildebrandt, M.G. The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma. Eur. J. Nucl. Med. Mol. Imaging 2022, 49, 2342–2351. [Google Scholar] [CrossRef] [PubMed]
- Arrangoiz, R.; Papavasiliou, P.; Stransky, C.A.; Yu, J.Q.; Tianyu, L.; Sigurdson, E.R.; Berger, A.C.; Farma, J.M. Preoperative FDG-PET/CT is an important tool in the management of patients with thick (T4) melanoma. Dermatol. Res. Pract. 2012, 2012, 614349. [Google Scholar] [CrossRef] [PubMed]
- Aukema, T.S.; Olmos, R.A.; Korse, C.M.; Kroon, B.B.; Wouters, M.W.; Vogel, W.V.; Bonfrer, J.M.; Nieweg, O.E. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up. Ann. Surg. Oncol. 2010, 17, 1657–1661. [Google Scholar] [CrossRef] [PubMed]
- Aukema, T.S.; Olmos, R.A.V.; Wouters, M.; Klop, W.M.C.; Kroon, B.R.; Vogel, W.V.; Nieweg, O.E. Utility of Preoperative 18F-FDG PET/CT and Brain MRI in Melanoma Patients with Palpable Lymph Node Metastases. Ann. Surg. Oncol. 2010, 17, 2773–2778. [Google Scholar] [CrossRef]
- Avilés Izquierdo, J.A.; Molina López, I.; Sobrini Morillo, P.; Márquez Rodas, I.; Mercader Cidoncha, E. Utility of PET/CT in patients with stage I–III melanoma. Clin. Transl. Oncol. 2020, 22, 1414–1417. [Google Scholar] [CrossRef]
- Bakare, A.N.; Agrawal, A.; Saklani, A.; Engineer, R.; Purandare, N.; Shah, S.; Puranik, A.; Rangarajan, V. Diagnostic performance of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in anorectal melanoma. World J. Nucl. Med. 2021, 20, 215–221. [Google Scholar] [CrossRef]
- Baker, J.J.; Meyers, M.O.; Frank, J.; Amos, K.D.; Stitzenberg, K.B.; Ollila, D.W. Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma. Am. J. Surg. 2014, 207, 549–554. [Google Scholar] [CrossRef]
- Barsky, M.; Cherkassky, L.; Vezeridis, M.; Miner, T.J. The role of preoperative positron emission tomography/computed tomography (PET/CT) in patients with high-risk melanoma. J. Surg. Oncol. 2014, 109, 726–729. [Google Scholar] [CrossRef]
- Bastiaannet, E.; Hoekstra, O.S.; de Jong, J.R.; Brouwers, A.H.; Suurmeijer, A.J.; Hoekstra, H.J. Prognostic value of the standardized uptake value for (18)F-fluorodeoxyglucose in patients with stage IIIB melanoma. Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 1592–1598. [Google Scholar] [CrossRef]
- Bastiaannet, E.; Oyen, W.J.; Meijer, S.; Hoekstra, O.S.; Wobbes, T.; Jager, P.L.; Hoekstra, H.J. Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br. J. Surg. 2006, 93, 243–249. [Google Scholar] [CrossRef]
- Bastiaannet, E.; Wobbes, T.; Hoekstra, O.S.; van der Jagt, E.J.; Brouwers, A.H.; Koelemij, R.; de Klerk, J.M.; Oyen, W.J.; Meijer, S.; Hoekstra, H.J. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: Diagnostic accuracy and impact on treatment. J. Clin. Oncol. 2009, 27, 4774–4780. [Google Scholar] [CrossRef]
- Belhocine, T.; Pierard, G.; De Labrassinn, M.; Lahaye, T.; Rigo, P. Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. Oncologist 2002, 7, 271–278. [Google Scholar] [CrossRef]
- Berzaczy, D.; Fueger, B.; Hoeller, C.; Haug, A.R.; Staudenherz, A.; Berzaczy, G.; Weber, M.; Mayerhoefer, M.E. Whole-Body [18F]FDG-PET/MRI vs. [18F]FDG-PET/CT in Malignant Melanoma. Mol. Imaging Biol. 2020, 22, 739–744. [Google Scholar] [CrossRef]
- Blessing, C.; Feine, U.; Geiger, L.; Carl, M.; Rassner, G.; Fierlbeck, G. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch. Dermatol. 1995, 131, 1394–1398. [Google Scholar] [CrossRef]
- Bohuslavizki, K.H.; Klutmann, S.; Neuber, K.; Wedler, J.; Altenhoff, J.; Kroger, S.; Buchert, R.; Bleckmann, C.; Clausen, M. Correlation of 18F-FDG-PET and histopathology in patients with malignant melanoma. Radiol. Oncol. 2000, 34, 1–9. [Google Scholar]
- Boni, R.; Huch Boni, R.A.; Steinert, H.; Burg, G.; Buck, A.; Marincek, B.; Berthold, T.; Dummer, R.; Voellmy, D.; Ballmer, B.; et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br. J. Dermatol. 1995, 132, 556–562. [Google Scholar] [CrossRef]
- Brady, M.S.; Akhurst, T.; Spanknebel, K.; Hilton, S.; Gonen, M.; Patel, A.; Larson, S. Utility of preoperative [(18)]F Fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann. Surg. Oncol. 2006, 13, 525–532. [Google Scholar] [CrossRef]
- Cha, J.; Kim, S.; Wang, J.; Yun, M.; Cho, A. Evaluation of 18F-FDG PET/CT Parameters for Detection of Lymph Node Metastasis in Cutaneous Melanoma. Nucl. Med. Mol. Imaging 2018, 52, 39–45. [Google Scholar] [CrossRef]
- Chandra, P.; Purandare, N.; Shah, S.; Agrawal, A.; Puri, A.; Gulia, A.; Rangarajan, V. Diagnostic Accuracy and Impact of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Preoperative Staging of Cutaneous Malignant Melanoma: Results of a Prospective Study in Indian Population. World J. Nucl. Med. 2017, 16, 286–292. [Google Scholar] [CrossRef]
- Clark, P.B.; Soo, V.; Kraas, J.; Shen, P.; Levine, E.A. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch. Surg. 2006, 141, 284–288. [Google Scholar] [CrossRef]
- Crippa, F.; Leutner, M.; Belli, F.; Gallino, F.; Greco, M.; Pilotti, S.; Cascinelli, N.; Bombardieri, E. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J. Nucl. Med. 2000, 41, 1491–1494. [Google Scholar]
- Damian, D.L.; Fulham, M.J.; Thompson, E.; Thompson, J.F. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res. 1996, 6, 325–329. [Google Scholar] [CrossRef]
- Eigtved, A.; Andersson, A.P.; Dahlstrøm, K.; Rabøl, A.; Jensen, M.; Holm, S.; Sørensen, S.S.; Drzewiecki, K.T.; Højgaard, L.; Friberg, L. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur. J. Nucl. Med. 2000, 27, 70–75. [Google Scholar] [CrossRef]
- El-Shourbagy, K.H.; Mashaly, E.M.; Khodair, S.A.; Houseni, M.M.; Abou Khadrah, R.S. PET/CT in restaging, prognosis, and recurrence in patients with malignant melanoma. Egypt. J. Radiol. Nucl. Med. 2020, 51, 167. [Google Scholar] [CrossRef]
- Eldon, M.; Kjerkegaard, U.K.; Orndrup, M.H.; Sjogren, P.; Stolle, L.B. Role of FDG-PET/CT in stage 1-4 malignant melanoma patients. Eur. J. Plast. Surg. 2017, 40, 47–52. [Google Scholar] [CrossRef]
- Essler, M.; Link, A.; Belloni, B.; Mirceva, V.; Souvatzoglou, M.; Thaler, M.; Haller, B.; Hein, R.; Krause, B.J. Prognostic value of [18F]-fluoro-deoxy-glucose PET/CT, S100 or MIA for assessment of cancer-associated mortality in patients with high risk melanoma. PLoS ONE 2011, 6, e24632. [Google Scholar] [CrossRef]
- Falk, M.S.; Truitt, A.K.; Coakley, F.V.; Kashani-Sabet, M.; Hawkins, R.A.; Franc, B. Interpretation, accuracy and management implications of fdg pet/ct in cutaneous malignant melanoma. Nucl. Med. Commun. 2007, 28, 273–280. [Google Scholar] [CrossRef]
- Fink, A.M.; Holle-Robatsch, S.; Herzog, N.; Mirzaei, S.; Rappersberger, K.; Lilgenau, N.; Jurecka, W.; Steiner, A. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res. 2004, 14, 141–145. [Google Scholar] [CrossRef]
- Finkelstein, S.E.; Carrasquillo, J.A.; Hoffman, J.M.; Galen, B.; Choyke, P.; White, D.E.; Rosenberg, S.A.; Sherry, R.M. A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann. Surg. Oncol. 2004, 11, 731–738. [Google Scholar] [CrossRef]
- Frary, E.C.; Gad, D.; Bastholt, L.; Hess, S. The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients. EJNMMI Res. 2016, 6, 73. [Google Scholar] [CrossRef]
- Fuster, D.; Chiang, S.; Johnson, G.; Schuchter, L.M.; Zhuang, H.; Alavi, A. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J. Nucl. Med. 2004, 45, 1323–1327. [Google Scholar]
- Gellén, E.; Sántha, O.; Janka, E.; Juhász, I.; Péter, Z.; Erdei, I.; Lukács, R.; Fedinecz, N.; Galuska, L.; Remenyik, É.; et al. Diagnostic accuracy of 18F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma. J. Eur. Acad. Dermatol. Venereol. 2015, 29, 1938–1944. [Google Scholar] [CrossRef]
- Ghanem, N.; Altehoefer, C.; Högerle, S.; Nitzsche, E.; Lohrmann, C.; Schäfer, O.; Kotter, E.; Langer, M. Detectability of liver metastases in malignant melanoma: Prospective comparison of magnetic resonance imaging and positron emission tomography. Eur. J. Radiol. 2005, 54, 264–270. [Google Scholar] [CrossRef]
- Gritters, L.S.; Francis, I.R.; Zasadny, K.R.; Wahl, R.L. Initial assessment of positron emission tomography using 2-fluorine-18- fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J. Nucl. Med. 1993, 34, 1420–1427. [Google Scholar]
- Gulec, S.A.; Faries, M.B.; Lee, C.C.; Kirgan, D.; Glass, C.; Morton, D.L.; Essner, R. The Role of Fluorine-18 Deoxyglucose Positron Emission Tomography in the Management of Patients with Metastatic Melanoma: Impact on Surgical Decision Making. Clin. Nucl. Med. 2003, 28, 961–965. [Google Scholar] [CrossRef]
- Hafner, J.; Schmid, M.H.; Kempf, W.; Burg, G.; Künzi, W.; Meuli-Simmen, C.; Neff, P.; Meyer, V.; Mihic, D.; Garzoli, E.; et al. Baseline staging in cutaneous malignant melanoma. Br. J. Dermatol. 2004, 150, 677–686. [Google Scholar] [CrossRef]
- Havenga, K.; Cobben, D.C.; Oyen, W.J.; Nienhuijs, S.; Hoekstra, H.J.; Ruers, T.J.; Wobbes, T. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur. J. Surg. Oncol. 2003, 29, 662–664. [Google Scholar] [CrossRef]
- Helvind, N.M.; Aros Mardones, C.A.; Hölmich, L.R.; Hendel, H.W.; Bidstrup, P.E.; Sørensen, J.A.; Chakera, A.H. Routine PET-CT scans provide early and accurate recurrence detection in asymptomatic stage IIB-III melanoma patients. Eur. J. Surg. Oncol. 2021, 47, 3020–3027. [Google Scholar] [CrossRef]
- Hinz, T.; Voth, H.; Ahmadzadehfar, H.; Hoeller, T.; Wenzel, J.; Bieber, T.; Schmid-Wendtner, M.H. Role of High-Resolution Ultrasound and PET/CT Imaging for Preoperative Characterization of Sentinel Lymph Nodes in Cutaneous Melanoma. Ultrasound Med. Biol. 2013, 39, 30–36. [Google Scholar] [CrossRef]
- Holder, W.D., Jr.; White, R.L., Jr.; Zuger, J.H.; Easton, E.J., Jr.; Greene, F.L. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann. Surg. 1998, 227, 764–769; discussion 769–771. [Google Scholar] [CrossRef] [PubMed]
- Holtkamp, L.H.J.; Chakera, A.H.; Fung, S.; Stretch, J.R.; Saw, R.P.M.; Lee, K.; Ch’Ng, S.; Gonzalez, M.; Thompson, J.F.; Emmett, L.; et al. Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases. Melanoma Res. 2020, 30, 358–363. [Google Scholar] [CrossRef] [PubMed]
- Holtkamp, L.H.J.; Read, R.L.; Emmett, L.; Thompson, J.F.; Nieweg, O.E. Futility of imaging to stage melanoma patients with a positive sentinel lymph node. Melanoma Res. 2017, 27, 457–462. [Google Scholar] [CrossRef] [PubMed]
- Horn, J.; Lock-Andersen, J.; Sjøstrand, H.; Loft, A. Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy. Eur. J. Nucl. Med. Mol. Imaging 2006, 33, 887–892. [Google Scholar] [CrossRef]
- Iagaru, A.; Quon, A.; Johnson, D.; Gambhir, S.S.; McDougall, I.R. 2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma. Mol. Imaging Biol. 2007, 9, 50–57. [Google Scholar] [CrossRef]
- Jouvet, J.C.; Thomas, L.; Thomson, V.; Yanes, M.; Journe, C.; Morelec, I.; Bracoud, L.; Durupt, F.; Giammarile, F.; Berthezene, Y. Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: A prospective study. J. Eur. Acad. Dermatol. Venereol. 2014, 28, 176–185. [Google Scholar] [CrossRef]
- Kell, M.R.; Ridge, J.A.; Joseph, N.; Sigurdson, E.R. PET CT imaging in patients undergoing sentinel node biopsy for melanoma. Eur. J. Surg. Oncol. 2007, 33, 911–913. [Google Scholar] [CrossRef]
- Klode, J.; Dissemond, J.; Grabbe, S.; Hillen, U.; Poeppel, T.; Boeing, C. Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: A retrospective analysis of 61 patients with malignant melanoma in American joint committee on cancer stages i and II. Dermatol. Surg. 2010, 36, 439–445. [Google Scholar] [CrossRef]
- Kokoska, M.S.; Olson, G.; Kelemen, P.R.; Fosko, S.; Dunphy, F.; Lowe, V.J.; Stack, B.C., Jr. The use of lymphoscintigraphy and PET in the management of head and neck melanoma. Otolaryngol. Head Neck Surg. 2001, 125, 213–220. [Google Scholar] [CrossRef]
- Koskivuo, I.; Kemppainen, J.; Giordano, S.; Seppänen, M.; Veräjänkorva, E.; Vihinen, P.; Minn, H. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma(). Acta Oncol. 2016, 55, 1355–1359. [Google Scholar] [CrossRef]
- Koskivuo, I.O.; Seppänen, M.P.; Suominen, E.A.; Minn, H.R. Whole body positron emission tomography in follow-up of high risk melanoma. Acta Oncol. 2007, 46, 685–690. [Google Scholar] [CrossRef] [PubMed]
- Lamarre, E.D.; Batra, P.S.; Lorenz, R.R.; Citardi, M.J.; Adelstein, D.J.; Srinivas, S.M.; Scharpf, J. Role of positron emission tomography in management of sinonasal neoplasms—A single institution’s experience. Am. J. Otolaryngol. 2012, 33, 289–295. [Google Scholar] [CrossRef] [PubMed]
- Laurent, V.; Trausch, G.; Bruot, O.; Olivier, P.; Felblinger, J.; Régent, D. Comparative study of two whole-body imaging techniques in the case of melanoma metastases: Advantages of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PET-CT. Eur. J. Radiol. 2010, 75, 376–383. [Google Scholar] [CrossRef] [PubMed]
- Lawal, I.; Lengana, T.; Ololade, K.; Boshomane, T.; Reyneke, F.; Modiselle, M.; Vorster, M.; Sathekge, M. 18 F-FDG PET/CT in the detection of asymptomatic malignant melanoma recurrence. NuklearMedizin 2017, 56, 83–89. [Google Scholar] [CrossRef] [PubMed]
- Lazaga, F.J.; Öz, O.K.; Adams-Huet, B.; Anderson, J.; Mathews, D. Comparison of whole-body versus limited whole-body 18F-FDG PET/CT scan in malignant cutaneous melanoma. Clin. Nucl. Med. 2013, 38, 882–884. [Google Scholar] [CrossRef] [PubMed]
- Leon-Ferre, R.A.; Kottschade, L.A.; Block, M.S.; McWilliams, R.R.; Dronca, R.S.; Creagan, E.T.; Allred, J.B.; Lowe, V.J.; Markovic, S.N. Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma. Melanoma Res. 2017, 27, 335–341. [Google Scholar] [CrossRef] [PubMed]
- Lewin, J.; Sayers, L.; Kee, D.; Walpole, I.; Sanelli, A.; Te Marvelde, L.; Herschtal, A.; Spillane, J.; Gyorki, D.; Speakman, D.; et al. Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma. Ann. Oncol. 2018, 29, 1569–1574. [Google Scholar] [CrossRef]
- Longo, M.I.; Lázaro, P.; Bueno, C.; Carreras, J.L.; Montz, R. Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients. Dermatol. Surg. 2003, 29, 245–248. [Google Scholar] [CrossRef]
- Macfarlane, D.J.; Sondak, V.; Johnson, T.; Wahl, R.L. Prospective evaluation of 2- F-18 -2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J. Clin. Oncol. 1998, 16, 1770–1776. [Google Scholar] [CrossRef]
- Madu, M.F.; Timmerman, P.; Wouters, M.W.J.M.; Van Der Hiel, B.; Van Der Hage, J.A.; Van Akkooi, A.C.J. PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: A prospective cohort study. Melanoma Res. 2017, 27, 251–257. [Google Scholar] [CrossRef]
- Mayerhoefer, M.E.; Prosch, H.; Herold, C.J.; Weber, M.; Karanikas, G. Assessment of pulmonary melanoma metastases with F-18-FDG PET/CT: Which PET-negative patients require additional tests for definitive staging? Eur. Radiol. 2012, 22, 2451–2457. [Google Scholar] [CrossRef] [PubMed]
- Paquet, P.; Henry, F.; Belhocine, T.; Hustinx, R.; Najjar, F.; Piérard-Franchimont, C.; Piérard, G.E.; Rigo, P. An appraisal of 18-fluorodeoxyglucose positron emission tomography for melanoma staging. Dermatology 2000, 200, 167–169. [Google Scholar] [CrossRef] [PubMed]
- Peric, B.; Zagar, I.; Novakovic, S.; Zgajnar, J.; Hocevar, M. Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma. BMC Cancer 2011, 11, 328. [Google Scholar] [CrossRef] [PubMed]
- Pfannenberg, C.; Aschoff, P.; Schanz, S.; Eschmann, S.M.; Plathow, C.; Eigentler, T.K.; Garbe, C.; Brechtel, K.; Vonthein, R.; Bares, R.; et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur. J. Cancer 2007, 43, 557–564. [Google Scholar] [CrossRef]
- Pfluger, T.; Melzer, H.I.; Schneider, V.; La Fougere, C.; Coppenrath, E.; Berking, C.; Bartenstein, P.; Weiss, M. PET/CT in malignant melanoma: Contrast-enhanced CT versus plain low-dose CT. Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 822–831. [Google Scholar] [CrossRef]
- Prakoso, E.; Fulham, M.; Thompson, J.F.; Selby, W.S. Capsule endoscopy versus positron emission tomography for detection of small-bowel metastatic melanoma: A pilot study. Gastrointest. Endosc. 2011, 73, 750–756. [Google Scholar] [CrossRef]
- Querellou, S.; Keromnes, N.; Abgral, R.; Sassolas, B.; Le Roux, P.Y.; Cavarec, M.B.; Le Duc-Pennec, A.; Couturier, O.; Salaun, P.Y. Clinical and therapeutic impact of 18F-FDG PET/CT whole-body acquisition including lower limbs in patients with malignant melanoma. Nucl. Med. Commun. 2010, 31, 766–772. [Google Scholar] [CrossRef]
- Reinhardt, M.J.; Wiethoelter, N.; Matthies, A.; Joe, A.Y.; Strunk, H.; Jaeger, U.; Biersack, H.J. PET recognition of pulmonary metastases on PET/CT imaging: Impact of attenuation-corrected and non-attenuation-corrected PET images. Eur. J. Nucl. Med. Mol. Imaging 2006, 33, 134–139. [Google Scholar] [CrossRef]
- Rinne, D.; Baum, R.P.; Hör, G.; Kaufmann, R. Primary staging and follow-up of high risk melanoma patients with whole- body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients. Cancer 1998, 82, 1664–1671. [Google Scholar] [CrossRef]
- Riquelme-Mc Loughlin, C.; Podlipnik, S.; Bosch-Amate, X.; Riera-Monroig, J.; Barreiro, A.; Espinosa, N.; Moreno-Ramírez, D.; Giavedoni, P.; Vilana, R.; Sánchez, M.; et al. Diagnostic accuracy of imaging studies for initial staging of T2b to T4b melanoma patients: A cross-sectional study. J. Am. Acad. Dermatol. 2019, 81, 1330–1338. [Google Scholar] [CrossRef]
- Roh, J.L.; Moon, B.J.; Kim, J.S.; Lee, J.H.; Cho, K.J.; Choi, S.H.; Nam, S.Y.; Lee, B.J.; Kim, S.Y. Use of 18F-fluorodeoxyglucose positron emission tomography in patients with rare head and neck cancers. Clin. Exp. Otorhinolaryngol. 2008, 1, 103–109. [Google Scholar] [CrossRef] [PubMed]
- Schaarschmidt, B.M.; Grueneisen, J.; Stebner, V.; Klode, J.; Stoffels, I.; Umutlu, L.; Schadendorf, D.; Heusch, P.; Antoch, G.; Pöppel, T.D. Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma? Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 2093–2102. [Google Scholar] [CrossRef] [PubMed]
- Schauwecker, D.S.; Siddiqui, A.R.; Wagner, J.D.; Davidson, D.; Jung, S.H.; Carlson, K.A.; Hutchins, G.D. Melanoma patients evaluated by four different positron emission tomography reconstruction techniques. Nucl. Med. Commun. 2003, 24, 281–289. [Google Scholar] [CrossRef] [PubMed]
- Singh, B.; Ezziddin, S.; Palmedo, H.; Reinhardt, M.; Strunk, H.; Tüting, T.; Biersack, H.J.; Ahmadzadehfar, H. Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. Melanoma Res. 2008, 18, 346–352. [Google Scholar] [CrossRef] [PubMed]
- Stahlie, E.H.A.; van der Hiel, B.; Bruining, A.; van de Wiel, B.; Schrage, Y.M.; Wouters, M.; van Houdt, W.J.; van Akkooi, A.C.J. The value of lymph node ultrasound and whole body (18)F-FDG PET/CT in stage IIB/C melanoma patients prior to SLNB. Eur. J. Surg. Oncol. 2021, 47, 1157–1162. [Google Scholar] [CrossRef]
- Stahlie, E.H.A.; van der Hiel, B.; Stokkel, M.P.M.; Schrage, Y.M.; van Houdt, W.J.; Wouters, M.W.; van Akkooi, A.C.J. The use of FDG-PET/CT to detect early recurrence after resection of high-risk stage III melanoma. J. Surg. Oncol. 2020, 122, 1328–1336. [Google Scholar] [CrossRef]
- Steinert, H.C.; Boni, R.A.H.; Buck, A.; Boni, R.; Berthold, T.; Marincek, B.; Burg, G.; Vonschulthess, G.K. Malignant-Melanoma—Staging with Whole-Body Positron Emission Tomography and 2- F-18 -Fluoro-2-Deoxy-D-Glucose. Radiology 1995, 195, 705–709. [Google Scholar] [CrossRef]
- Strobel, K.; Bode, B.; Dummer, R.; Veit-Haibach, P.; Fischer, D.R.; Imhof, L.; Goldinger, S.; Steinert, H.C.; Von Schulthess, G.K. Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 1774–1782. [Google Scholar] [CrossRef]
- Strobel, K.; Dummer, R.; Husarik, D.B.; Lago, M.P.; Hany, T.F.; Steinert, H.C. High-risk melanoma: Accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007, 244, 566–574. [Google Scholar] [CrossRef]
- Strobel, K.; Skalsky, J.; Kalff, V.; Baumann, K.; Seifert, B.; Joller-Jemelka, H.; Dummer, R.; Steinert, H.C. Tumour assessment in advanced melanoma: Value of FDG-PET/CT in patients with elevated serum S-100B. Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 1366–1375. [Google Scholar] [CrossRef]
- Swetter, S.M.; Carroll, L.A.; Johnson, D.L.; Segall, G.M. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann. Surg. Oncol. 2002, 9, 646–653. [Google Scholar] [CrossRef] [PubMed]
- Turner, R.M.; Dieng, M.; Khanna, N.; Nguyen, M.; Zeng, J.; Nijhuis, A.A.G.; Nieweg, O.E.; Einstein, A.J.; Emmett, L.; Lord, S.J.; et al. Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA–D Melanoma. Ann. Surg. Oncol. 2021, 28, 4561–4569. [Google Scholar] [CrossRef] [PubMed]
- Tyler, D.S.; Onaitis, M.; Kherani, A.; Hata, A.; Nicholson, E.; Keogan, M.; Fisher, S.; Coleman, E.; Seigler, H.F. Positron emission tomography scanning in malignant melanoma—Clinical utility in patients with Stage III disease. Cancer 2000, 89, 1019–1025. [Google Scholar] [CrossRef] [PubMed]
- van Wissen, J.; van der Hiel, B.; van der Hage, J.A.; van de Wiel, B.A.; Wouters, M.; van Akkooi, A.C.J. The Diagnostic Value of PET/CT Imaging in Melanoma Groin Metastases. Ann. Surg. Oncol. 2016, 23, 2323–2329. [Google Scholar] [CrossRef] [PubMed]
- Veit-Haibach, P.; Vogt, F.M.; Jablonka, R.; Kuehl, H.; Bockisch, A.; Beyer, T.; Dahmen, G.; Rosenbaum, S.; Antoch, G. Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 910–918. [Google Scholar] [CrossRef] [PubMed]
- Vensby, P.H.; Schmidt, G.; Kjær, A.; Fischer, B.M. The value of FDG PET/CT for follow-up of patients with melanoma: A retrospective analysis. Am. J. Nucl. Med. Mol. Imaging 2017, 7, 255–262. [Google Scholar] [PubMed]
- Vereecken, P.; Laporte, M.; Petein, M.; Steels, E.; Heenen, M. Evaluation of extensive initial staging procedure in intermediate/high-risk melanoma patients. J. Eur. Acad. Dermatol. Venereol. 2005, 19, 66–73. [Google Scholar] [CrossRef]
- Vural Topuz, Ö.; Görtan, F.A.; Kaya Döner, Z.R.; Önsel, Ç.; Sayman, H.B. Usefulness of (18)F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels. Mol. Imaging Radionucl. Ther. 2018, 27, 66–72. [Google Scholar] [CrossRef]
- Wagner, J.D.; Schauwecker, D.; Davidson, D.; Coleman Iii, J.J.; Saxman, S.; Hutchins, G.; Love, C.; Hayes, J.T. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J. Clin. Oncol. 1999, 17, 1508–1515. [Google Scholar] [CrossRef]
- Wagner, J.D.; Schauwecker, D.; Davidson, D.; Logan, T.; Coleman Iii, J.J.; Hutchins, G.; Love, C.; Wenck, S.; Daggy, J. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 2005, 104, 570–579. [Google Scholar] [CrossRef]
- Wagner, J.D.; Schauwecker, D.S.; Davidson, D.; Wenck, S.; Jung, S.H.; Hutchins, G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J. Surg. Oncol. 2001, 77, 237–242. [Google Scholar] [CrossRef] [PubMed]
- Wagner, T.; Chevreau, C.; Meyer, N.; Mourey, L.; Courbon, F.; Zerdoud, S. Routine FDG PET-CT in patients with a high-risk localized melanoma has a high predictive positive value for nodal disease and high negative predictive value for the presence of distant metastases. J. Eur. Acad. Dermatol. Venereol. 2012, 26, 1431–1435. [Google Scholar] [CrossRef] [PubMed]
- Wieder, H.A.; Tekin, G.; Rosenbaum-Krumme, S.; Klode, J.; Altenbernd, J.; Bockisch, A.; Nagarajah, J. 18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma. NuklearMedizin 2013, 52, 198–203. [Google Scholar] [CrossRef] [PubMed]
- Yancovitz, M.; Finelt, N.; Warycha, M.A.; Christos, P.J.; Mazumdar, M.; Shapiro, R.L.; Pavlick, A.C.; Osman, I.; Polsky, D.; Berman, R.S. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer 2007, 110, 1107–1114. [Google Scholar] [CrossRef] [PubMed]
- Zimmermann, P.A.; Houdu, B.; Césaire, L.; Nakouri, I.; De Pontville, M.; Lasnon, C.; Aide, N. Revisiting detection of in-transit metastases in melanoma patients using digital 18F-FDG PET/CT with small-voxel reconstruction. Ann. Nucl. Med. 2021, 35, 669–679. [Google Scholar] [CrossRef] [PubMed]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef] [PubMed]
- Hardie, C.M.; Allouni, A.; Edwards, S.; Ahmed, N.; Maraveyas, A.; Matteucci, P.L. PET-CT for staging pT4b melanomas prior to sentinel lymph node biopsy: A 5-year review. Melanoma Res. 2021, 31, 397–401. [Google Scholar] [CrossRef] [PubMed]
- Xing, Y.; Bronstein, Y.; Ross, M.I.; Askew, R.L.; Lee, J.E.; Gershenwald, J.E.; Royal, R.; Cormier, J.N. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: A meta-analysis. J. Natl. Cancer Inst. 2011, 103, 129–142. [Google Scholar] [CrossRef]
- Perng, P.; Marcus, C.; Subramaniam, R.M. 18F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis. Am. J. Roentgenol. 2015, 205, 259–270. [Google Scholar] [CrossRef]
- Jiménez-Requena, F.; Delgado-Bolton, R.C.; Fernández-Pérez, C.; Gambhir, S.S.; Schwimmer, J.; Pérez-Vázquez, J.M.; Carreras-Delgado, J.L. Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 284–300. [Google Scholar] [CrossRef]
- Sánchez-Sánchez, R.; Serrano-Falcón, C.; Rebollo Aguirre, A.C. Diagnostic imaging in dermatology: Utility of PET-CT in cutaneous melanoma. Actas Dermosifiliogr. 2015, 106, 29–34. [Google Scholar] [CrossRef] [PubMed]
- Maubec, E.; Lumbroso, J.; Masson, F.; Suciu, V.; Kolb, F.; Mamelle, G.; Cavalcanti, A.; Boitier, F.; Spatz, A.; Aupérin, A. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. Melanoma Res. 2007, 17, 147–154. [Google Scholar] [CrossRef] [PubMed]
- Bisschop, C.; de Heer, E.C.; Brouwers, A.H.; Hospers, G.A.P.; Jalving, M. Rational use of 18F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review. Crit. Rev. Oncol./Hematol. 2020, 153, 103044. [Google Scholar] [CrossRef] [PubMed]
- Müller-Horvat, C.; Radny, P.; Eigentler, T.K.; Schäfer, J.; Pfannenberg, C.; Horger, M.; Khorchidi, S.; Nägele, T.; Garbe, C.; Claussen, C.D.; et al. Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. Eur. J. Cancer 2006, 42, 342–350. [Google Scholar] [CrossRef] [PubMed]
- Steinert, H.C. PET and PET/CT of malignant melanoma. In Skin Cancer—A World-Wide Perspective; Springer: Berlin, Germany, 2011; pp. 379–390. [Google Scholar]
- Sabel, M.S.; Wong, S.L. Review of evidence-based support for pretreatment imaging in melanoma. J. Natl. Compr. Cancer Netw. 2009, 7, 281–289. [Google Scholar] [CrossRef] [PubMed]
- Garbe, C.; Paul, A.; Kohler-Späth, H.; Ellwanger, U.; Stroebel, W.; Schwarz, M.; Schlagenhauff, B.; Meier, F.; Schittek, B.; Blaheta, H.-J.; et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: Recommendations for an effective follow-up strategy. J. Clin. Oncol. 2003, 21, 520–529. [Google Scholar] [CrossRef]
- Spencer, K.R.; Mehnert, J.M. Mucosal Melanoma: Epidemiology, Biology and Treatment. In Melanoma; Kaufman, H.L., Mehnert, J.M., Eds.; Springer International Publishing: Cham, Switzerland, 2016; pp. 295–320. [Google Scholar]
- Lee, C.C.; Faries, M.B.; Wanek, L.A.; Morton, D.L. Improved survival for stage IV melanoma from an unknown primary site. J. Clin. Oncol. 2009, 27, 3489. [Google Scholar] [CrossRef]
- Tos, T.; Klyver, H.; Drzewiecki, K.T. Extensive screening for primary tumor is redundant in melanoma of unknown primary. J. Surg. Oncol. 2011, 104, 724–727. [Google Scholar] [CrossRef]
- Kole, A.C.; Nieweg, O.E.; Pruim, J.; Hoekstra, H.J.; Koops, H.S.; Roodenburg, J.L.; Vaalburg, W.; Vermey, A. Detection of unknown occult primary tumors using positron emission tomography. Cancer Interdiscip. Int. J. Am. Cancer Soc. 1998, 82, 1160–1166. [Google Scholar] [CrossRef]
- Pelosi, E.; Pennone, M.; Deandreis, D.; Douroukas, A.; Mancini, M.; Bisi, G. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q. J. Nucl. Med. Mol. Imaging 2006, 50, 15–22. [Google Scholar]
Author, Year [Ref.] | Modality | Reference Standard | Level of Analysis | Number of Included Patients or Lesions |
---|---|---|---|---|
Acland, 2000 [12] | PET | Histopathology, Follow-up | P | 52 |
Aerts, 2012 [13] | PET/CT | Capsule Endoscopy | P | 9 |
Agrawal, 2017 [14] | PET/CT | Histopathology, Follow-up | P | 19 |
Akcali, 2007 [15] | PET/CT | Histopathology | P | 38 |
Albano, 2020 [16] | PET/CT | Histopathology, Follow-up | P | 74 |
Andersen, 2022 [17] | PET/CT | Histopathology, MRI, Follow-up | P | 124 |
Arrangoiz, 2012 [18] | PET/CT | Histopathology | P | 56 |
Aukema, 2010_1 [19] | PET/CT | Histopathology, Further imaging, Follow-up | P | 46 |
Aukema, 2010_2 [20] | PET/CT | Histopathology, Further imaging, Follow-up | P | 70 |
Avilés Izquierdo, 2020 [21] | PET/CT | Histopathology | P | 83 |
Bakare, 2021 [22] | PET/CT | Histopathology, Follow-up | P | 61 |
Baker, 2014 [23] | PET/CT | Histopathology, Follow-up | P | 38 |
Barsky, 2014 [24] | PET/CT | Histopathology | P | 149 |
Bastiaannet, 2006 [26] | PET | Histopathology, Follow-up | P | 257 |
Bastiaannet, 2009 [27] | PET | Histopathology, Further imaging, Follow-up | P | 251 |
Bastiaannet, 2012 [25] | PET | Histopathology, CT scan, Follow-up | P | 253 |
Belhocine, 2002 [28] | PET | Histopathology | P | 21 |
Berzaczy, 2020 [29] | PET/CT | Histopathology, Follow-up | L | 160 |
PET/MRI | ||||
Blessing, 1995 [30] | PET | Histopathology, Further imaging, Follow-up | L | 83 |
Bohuslavizki, 2000 [31] | PET | Histopathology | L | 189 |
Böni, 1995 [32] | PET | Histopathology, Further imaging | L | 39 |
Brady, 2006 [33] | PET | Histopathology, CT scan, Follow-up | P | 103 |
Cha, 2018 [34] | PET/CT | Histopathology | L | 165 |
Chandra, 2017 [35] | PET/CT | Histopathology, Follow-up | P | 70 |
Clark, 2006 [36] | PET | Histopathology | P | 64 |
Crippa, 2000 [37] | PET | Histopathology | P | 38 |
L | 56 | |||
Damian, 1996 [38] | PET | Histopathology, Further imaging | L | 639 |
Eigtved, 2000 [39] | PET | Histopathology, Further imaging, Follow-up | P | 38 |
El-Shourbagy, 2020 [40] | PET/CT | Histopathology, CT scan | P | 50 |
Eldon, 2017 [41] | PET/CT | Histopathology, Further imaging, Follow-up | P | 58 |
Essler, 2011 [42] | PET/CT | Histopathology, Further imaging, Follow-up | P | 125 |
Falk, 2007 [43] | PET/CT | Histopathology, Further imaging, Follow-up | P | 60 |
Fink, 2004 [44] | PET/CT | Histopathology | P | 48 |
Finkelstein, 2004 [45] | PET/CT | Histopathology, Follow-up | L | 94 |
Frary, 2016 [46] | PET/CT | Histopathology, Follow-up | P | 46 |
Fuster, 2004 [47] | PET | Histopathology, CT scan, Follow-up | L | 146 |
Gellén, 2015 [48] | PET/CT | Histopathology, Follow-up | P | 97 |
Ghanem, 2005 [49] | PET | MRI, Follow-up | P | 35 |
Gritters, 1993 [50] | PET | Histopathology, Further imaging, Follow-up | P | 12 |
L | 52 | |||
Gulec, 2003 [51] | PET | Histopathology, Further imaging | L | 44 |
Hafner, 2004 [52] | PET | Histopathology, Follow-up | P | 100 |
Havenga, 2003 [53] | PET | Histopathology | P | 45 |
Helvind, 2021 [54] | PET/CT | Histopathology | P | 138 |
Hinz, 2013 [55] | PET/CT | Histopathology | L | 59 |
Holder, 1998 [56] | PET | Histopathology, CT scan | P | 76 |
Holtkamp, 2017 [58] | PET/CT | Histopathology, Follow-up | P | 41 |
Holtkamp, 2020 [57] | PET/CT | Histopathology, Follow-up | P | 25 |
Horn, 2006 [59] | PET | Histopathology, Further imaging, Follow-up | P | 33 |
Iagaru, 2007 [60] | PET/CT | Histopathology, Follow-up | P | 106 |
L | 139 | |||
Izquierdo, 2020 [21] | PET/CT | Histopathology | P | 83 |
Jouvet, 2014 [61] | PET/CT | Histopathology, Follow-up | L | 191 |
Kell, 2007 [62] | PET/CT | Histopathology | P | 37 |
Klode, 2010 [63] | PET/CT | Histopathology | P | 61 |
L | 174 | |||
Kokoska, 2001 [64] | PET | Histopathology | P | 18 |
L | 63 | |||
Koskivuo, 2007 [66] | PET | Histopathology, Follow-up | P | 30 |
Koskivuo, 2016 [65] | PET/CT | Histopathology, Follow-up | P | 110 |
Lamarre, 2012 [67] | PET/CT | Histopathology, Follow-up | P | 19 |
Laurent, 2010 [68] | PET/CT | Histopathology, Further imaging, Follow-up | L | 120 |
Lawal, 2017 [69] | PET/CT | Histopathology, Follow-up | P | 144 |
Lazaga, 2013 [70] | PET/CT | Histopathology, Follow-up | P | 200 |
Leon-Ferre, 2017 [71] | PET/CT | Histopathology, Follow-up | P | 299 |
Lewin, 2018 [72] | PET/CT | Histopathology, Further imaging, Follow-up | P | 47 |
Longo, 2003 [73] | PET | Histopathology | P | 25 |
Macfarlane, 1998 [74] | PET | Histopathology | P | 22 |
Madu, 2017 [75] | PET/CT | Histopathology, Further imaging, Follow-up | P | 18 |
Mayerhoefer, 2012 [76] | PET/CT | Histopathology, Follow-up | P | 38 |
L | 181 | |||
Paquet, 2000 [77] | PET | Histopathology, Follow-up | P | 24 |
Peric, 2011 [78] | PET/CT | Histopathology, Further imaging | P | 115 |
Pfannenberg, 2007 [79] | PET/CT | Histopathology, Follow-up | L | 420 |
PET | ||||
Pfluger, 2011 [80] | PET/CT | Histopathology, Follow-up | L | 232 |
Prakoso, 2011 [81] | PET/CT | Capsule Endoscopy, Follow-up | P | 21 |
Querellou, 2010 [82] | PET/CT | Histopathology, Follow-up | P | 189 |
Reinhardt, 2006 [83] | PET/CT | Histopathology, Follow-up | P | 250 |
PET | ||||
Rinne, 1998 [84] | PET | Histopathology, Further imaging, Follow-up | P | 100 |
L | 121 | |||
Riquelme-Mc Loughlin, 2019 [85] | PET/CT | Histopathology, Further imaging, Follow-up | P | 61 |
Roh, 2008 [86] | PET | Histopathology | P | 10 |
Schaarschmidt, 2018 [87] | PET/MRI | Histopathology | L | 87 |
PET/CT | ||||
Schauwecker, 2003 [88] | PET | Histopathology | P | 119 |
Singh, 2008 [89] | PET/CT | Histopathology | P | 54 |
Stahlie, 2020 [91] | PET/CT | Histopathology | P | 35 |
Stahlie, 2021 [90] | PET/CT | Histopathology | P | 23 |
Steinert, 1995 [92] | PET | Histopathology, Further imaging | L | 53 |
Strobel, 2007 [94] | PET/CT | Histopathology, Further imaging, Follow-up | P | 124 |
PET | ||||
Strobel, 2007 [95] | PET/CT | Histopathology, Further imaging, Follow-up | P | 47 |
Strobel, 2009 [93] | PET/CT | Histopathology, Further imaging, Follow-up | P | 14 |
Swetter, 2002 [96] | PET | Histopathology, Further imaging, Follow-up | L | 199 |
Turner, 2021 [97] | PET/CT | Histopathology, Further imaging, Follow-up | P | 332 |
Tyler, 2000 [98] | PET | Histopathology | L | 234 |
van Wissen, 2016 [99] | PET/CT | Histopathology | P | 70 |
Veit-Haibach, 2009 [100] | PET/CT | Histopathology, Further imaging, Follow-up | P | 56 |
Vensby, 2017 [101] | PET/CT | Histopathology, Further imaging, Follow-up | P | 238 |
Vereecken, 2005 [102] | PET/CT | Histopathology, Follow-up | P | 43 |
L | 43 | |||
Vural Topuz, 2018 [103] | PET/CT | Histopathology | P | 65 |
Wagner, 1999 [104] | PET | Histopathology | L | 89 |
Wagner, 2001 [106] | PET | Histopathology | L | 49 |
Wagner, 2005 [105] | PET | Histopathology, Follow-up | L | 184 |
Wagner, 2012 [107] | PET/CT | Histopathology | P | 49 |
Wieder, 2013 [108] | PET/CT | Histopathology, Follow-up | P | 28 |
Yancovitz, 2007 [109] | PET/CT | Histopathology, Further imaging, Follow-up | P | 36 |
Zimmermann, 2021 [110] | PET/CT | Histopathology, Follow-up | P | 44 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zamani-Siahkali, N.; Mirshahvalad, S.A.; Pirich, C.; Beheshti, M. Diagnostic Performance of [18F]F-FDG Positron Emission Tomography (PET) in Non-Ophthalmic Malignant Melanoma: A Systematic Review and Meta-Analysis of More Than 10,000 Melanoma Patients. Cancers 2024, 16, 215. https://doi.org/10.3390/cancers16010215
Zamani-Siahkali N, Mirshahvalad SA, Pirich C, Beheshti M. Diagnostic Performance of [18F]F-FDG Positron Emission Tomography (PET) in Non-Ophthalmic Malignant Melanoma: A Systematic Review and Meta-Analysis of More Than 10,000 Melanoma Patients. Cancers. 2024; 16(1):215. https://doi.org/10.3390/cancers16010215
Chicago/Turabian StyleZamani-Siahkali, Nazanin, Seyed Ali Mirshahvalad, Christian Pirich, and Mohsen Beheshti. 2024. "Diagnostic Performance of [18F]F-FDG Positron Emission Tomography (PET) in Non-Ophthalmic Malignant Melanoma: A Systematic Review and Meta-Analysis of More Than 10,000 Melanoma Patients" Cancers 16, no. 1: 215. https://doi.org/10.3390/cancers16010215